---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002291"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:25:11.064116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M

## Summary
- Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).
- Q4 net loss $43.1M ($0.27/sh) vs. $66.8M ($0.42/sh) in Q4 2020; full-year loss $167.9M ($1.05/sh).
- Resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis; Phase 3 Lavender trial of trofinetide in Rett syndrome positive.
- FY2022 guidance: NUPLAZID net sales $510-560M; R&D expense $355-375M; SG&A $360-380M.
- Cash and investments $520.7M at Dec 31, 2021, down from $632.0M a year earlier.

## SEC filing metadata
- accession: 0000950170-22-002291
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/0000950170-22-002291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/acad-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002291
- JSON: https://secwatch.observer/filing/0000950170-22-002291.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.